🇨🇭#RO #отчетность
Roche
Q1 Group sales = +11% to CHF16.45B
Pharmaceuticals Division sales = +6% to CHF11.2B
Ronapreve (REGEN-COV) sales = +272% to CHF 587M.
Roche
Q1 Group sales = +11% to CHF16.45B
Pharmaceuticals Division sales = +6% to CHF11.2B
Ronapreve (REGEN-COV) sales = +272% to CHF 587M.
⚡️🇪🇺#RO #отчетность
Roche H1 22 Earnings
- H1 Core EPS CHF 11.76 (est CHF 11.05)
- H1 Revenue CHF 32.03B (est CHF 31.89B)
- Confirms FY 22 Outlook
Roche H1 22 Earnings
- H1 Core EPS CHF 11.76 (est CHF 11.05)
- H1 Revenue CHF 32.03B (est CHF 31.89B)
- Confirms FY 22 Outlook
🇨🇭#RO #отчетность
Roche Q4, FY 22 Earnings:
- Rev CHF16.24B (est CHF16.12B)
- Diagnostics Sales CHF3.88B (est CHF3.79B)
- FY Sales CHF63.28B (est CHF63.29B)
- FY Core EPS CHF20.30 (est CHF20.61)
- Sees 2023 Sales Fall In Low Single Digits At Constant FX
Roche Q4, FY 22 Earnings:
- Rev CHF16.24B (est CHF16.12B)
- Diagnostics Sales CHF3.88B (est CHF3.79B)
- FY Sales CHF63.28B (est CHF63.29B)
- FY Core EPS CHF20.30 (est CHF20.61)
- Sees 2023 Sales Fall In Low Single Digits At Constant FX
🇨🇭#RO #отчетность
Roche H1 23 Earnings:
- Confirms Outlook For 2023
- Core EPS: CHF10.10 (exp CHF10.15)
- Revenue: CHF29.78B (exp CHF30.09B)
Roche H1 23 Earnings:
- Confirms Outlook For 2023
- Core EPS: CHF10.10 (exp CHF10.15)
- Revenue: CHF29.78B (exp CHF30.09B)